Loading…

Mani, Inc.7730.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum neutral 49
Mkt cap
$965M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$3.08M
20-day average traded
Fwd P/E
19.9×
forward earnings
ROIC−WACC
+13.0 pp
WACC 8.2%
Hurdle
-11 pp
Req g minus delivered
Next earnings
56 days
13 Jan 2027
Close · JPY¥1,552
1D+0.5%
1W+4.2%
1M+1.2%
3M-4.2%
6M-6.8%
YTD+7.0%
1Y+5.9%
ATR %2.3%
52w lowhigh20.6% off high

What Mani does

No business profile yet.

Mani at a glance

Size Mani (7730.T) is a Japan Health Care company (Medical Specialties) with a market value of $965M, the 756th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,552 on 18 Nov 2026.

Performance Over six months the shares fell 6.8%, against -11.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 10.2% over the last twelve months (peer median +10.4%); the operating margin is 30.1% (peer median 9.6%).

Valuation It trades at 19.9× forward earnings against a peer median of 20.9× (8th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.0 points above its cost of capital (8.2% WACC).

Next results Next results expected around 13 Jan 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 20267730.T 92Peer median 88
Six months, rebased to 100: Mani against the median of its 20 peers (local-currency closes).

Mani financials

Reported figures in JPY; fiscal year ends 2026-08-31. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue¥33.0B¥33.0B¥30.0B¥28.5B¥24.5B
Revenue growth—+10%+5%+16%—
Gross profit¥22.0B¥22.0B¥18.9B¥17.5B¥15.1B
EBITDA¥12.4B¥12.4B¥10.7B¥10.7B¥9.16B
Net income¥7.24B¥7.24B¥4.64B¥6.29B¥5.95B
Free cash flown/a¥10.7B¥612M¥397M¥4.52B
Capital expendituren/a¥1.15B¥6.67B¥7.68B¥3.72B
Total debt¥81.0M¥81.0M¥76.0M¥83.0M¥58.0M

Quarterly statements and history in the cockpit →

Mani competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%3046SFL3001437780290650CBLL3002063006856523301021600055KURNEUZCSTLAORTBVS301580IRMD6885757730.T6-month return →1-month return →
Up and to the right = strong over both horizons. Mani is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×3046SFL3001437780300206300685KURNAORTIRMD6887677730.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mani is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%3046SFL3001432906503002063006856523301021EUZCSTLBVS301580IRMD6885757730.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mani is the large dot.

Mani competitors and peer comparison

How Mani compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mani against its 20 peers (data as of 18 Nov 2026)
Measure7730.TPeer medianRank in peer set
1-month return+1.2%-6.0%7th highest of 21
6-month return-6.8%-11.7%8th highest of 21
Distance from 52-week high-20.6%-30.5%5th highest of 21
Revenue growth (TTM)+10.2%+10.4%11th highest of 21
Operating margin30.1%9.6%3rd highest of 21
Forward P/E19.9×20.9×8th cheapest of 16
Growth the price implies (Req g, 7 yrs)3.3%7.6%5th least demanding of 15
Growth delivered (Del g)+13.9%+12.1%5th highest of 15
Hurdle (Req g minus delivered)-10.7 pp-3.7 pp2nd least demanding of 15
ROIC minus cost of capital+13.0 pp+2.8 pp6th highest of 20
EV / EBITDA10.3×10.4×6th cheapest of 11
Net debt / EBITDA-2.1×0.3×least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a

Questions

Which companies are Mani's closest peers?
The cockpit's peer set: JINS (3046.T), Safilo (SFL.MI), INKON Life Technology (300143.SZ), Menicon (7780.T), L&C BIO (290650.KS), Ceribell (CBLL), Edan Instruments (300206.SZ), Amoy Diagnostics (300685.SZ).
Is Mani expensive compared with its peers?
On forward p/e it trades at 19.9× against a peer median of 20.9×, 8th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Mani stock performed?
Over six months to 18 Nov 2026 the shares returned -6.8% against -11.7% for the median peer; over one year +5.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.